Table 1.
Overview of novel agents discussed in this review and their targets.
| Drug | Target |
|---|---|
| Monoclonal Antibodies | |
| Obinutuzumab | CD20 |
| Ofatumumab | CD20 |
| Epratuzumab | CD22 |
| Lucatumumab | CD40 |
| MEDI-551 | CD19 |
| Antibody Drug Conjugates | |
| Brentuximab vedotin | CD30 |
| Polatuzumab vedotin | CD79b |
| Inotuzumab ozogamicin | CD22 |
| SAR3419 | CD19 |
| SGN-CD19A | CD19 |
| Bispecific T-cell Engager | |
| Blinatumomab | CD19/CD3 |
| Immune Checkpoint Inhibitors | |
| Ipilimumab | CTLA-4 |
| Pidilizumab | PD-1 |
| Nivolumab | PD-1 |
| Pembrolizumab | PD-1 |
| MPDL3280A | PDL-1 |
| Small Molecule Inhibitors | |
| Ibrutinib | BTK |
| Idelalisib | PI3Kδ |
| Duvelisib | PI3Kγδ |
| TGR-1202 | PI3Kδ |
| Copanlisib | PI3Kαδ |
| INCB040093 | PI3Kδ |
| INCB039110 | JAK1 |
| Pacritinib | JAK2 |
| Navitoclax | Bcl-2 |
| Venetoclax | Bcl-2 |
| Alisertib | Aurora kinase A |